Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Depreciation and Depletion (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Depreciation and Depletion for 5 consecutive years, with $800000.0 as the latest value for Q1 2023.

  • Quarterly Depreciation and Depletion rose 33.33% to $800000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $800000.0 through Mar 2023, down 63.64% year-over-year, with the annual reading at $600000.0 for FY2022, 71.43% down from the prior year.
  • Depreciation and Depletion for Q1 2023 was $800000.0 at Marker Therapeutics, up from -$1.4 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $800000.0 in Q3 2022, with the low at -$1.4 million in Q4 2022.
  • Average Depreciation and Depletion over 5 years is $235294.1, with a median of $200000.0 recorded in 2020.
  • The sharpest move saw Depreciation and Depletion skyrocketed 1566.67% in 2021, then tumbled 380.0% in 2022.
  • Over 5 years, Depreciation and Depletion stood at $30000.0 in 2019, then soared by 566.67% to $200000.0 in 2020, then skyrocketed by 150.0% to $500000.0 in 2021, then crashed by 380.0% to -$1.4 million in 2022, then soared by 157.14% to $800000.0 in 2023.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $800000.0, -$1.4 million, and $800000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.